Fig. 1: Association of EZH2 expression and lytic bone lesion in myeloma.
From: EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
a In a published GEO dataset (GSE755), EZH2 mRNA levels were compared in primary myeloma cells from 37 patients without bone lesions (BL = 0) and 136 patients with bone lesions (BL ≥ 1). Data are means ± SD. p value was determined by unpaired two-tailed t test. b Primary myeloma cells were isolated from bone marrow aspirates of 30 newly diagnosed patients, some with and some without bone lesions. Shown are correlation coefficient of the mRNA levels of EZH2 and numbers of bone lesion in patients (n = 30). The correlation was evaluated using Pearson coefficient with two-tailed p value. r, correlation coefficient. Representative images of magnetic resonance imaging and x-ray scanning for lytic lesions in the skull (c) and spine (d) in patient 1 (P1: 25 bone lesions) and patient 2 (P2: 4 bone lesions). Yellow arrow, bone lesion. Scale bar, 1 cm. e, f Representative images of immunohistochemical staining and densitometry analysis show the expression of CD138 and EZH2 in the biopsy segment of two patients (P1 and P2) (n = 6 areas/patient). e is representative of three independent experiments. Scale bar, 30 µm. p values were determined by unpaired two-tailed t test. Source data are provided as a Source data file.
